权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

REDUCTION OF ISCHEMIA-REPERFUSION INJURY TO SKIN FLAP MODEL BY MONOCLONAL ANTIBODY TO ADHESION MOLECULE-EXPERIMENTAL STUDY-

粘附分子单克隆抗体减少皮瓣模型缺血再灌注损伤-实验研究-

基本信息

批准号：
12671752
负责人：
TOSA Yasuyoshi
金额：
$ 2.11万
依托单位：
SHOWA UNIVERSITY
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2000
资助国家：
日本
起止时间：
2000 至 2002
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-12671752/
关键词：
MONOCLONAL ANTIBODY ISCHEMIA-REPERFUSION INJURY SKIN FLAP MODEL ANTIBODY TO LECAM-1 ANTIBODY TO VLA-4 ANTIBODY TO VCAM-1 TACROLIMUS Sptrague-Dawley RAT 虚血再潅流障害抗ICAM-1抗体抗LFA-1抗体抗CP-2抗体抗LLF-3抗体 Spragw-Dawleyラット

项目摘要

Aim : Ischemia-reperfusion(I-R) injury continues to be a problem for successful free tissue transfer and replantation after prolonged periods of ischemia. It has been shown that leukocytes and vascular endothelial cells release a variety of inflammatory mediators during reperfusion after ischemia. The vascular cell adhesion molecule-1 (VCAM-1) is a ligand on the endothelium for some of the adhesion receptors on leukocytes. The purpose of this study was to evaluate the blockage of leukocyte-endothelial adhesion by a monoclonal antibody (MAb) to VCAM-1/VLA-4, Tacrolimus, LECAM-1 in skin flaps to prevent I-R injury in rats.Methods : Male SD rats (225-250gr) were used. A skin flap (45×30mm) supplied by the superficial epigastric A&V including the femoral vessels was isolated unilaterally. The femoral vessels were cross-clamped the epigastric vessels for 9 hours of ischemia. Animals in treated group received MAb to VCAM-1/VLA-4, Tacrolimus, LECAM-1 i.v. 15 minutes prior to reperfusion ; those in the control group received normal saline. Skin flap viability was assessed by tracing the outline of viable and nonviable areas. Data were collected for the following 7 days. These data were corroborated with histological evidence on comparable areas of the flap.Results : Tracing analysis revealed average flap survival area of about 70% in treated group and about 20% in control group (p<0.05). Histopathologically, few inflammatory changes could be observed in treated group, while marked damage was observed in control group.Conclusions : From this study, we concluded that treating skin flaps with Mab to VCAM-1, Tacrolimus, LECAM-1 was effective for I-R injury after 9 hours of warm ischemia.

目的：缺血-再灌注（I-R）损伤仍然是长时间缺血后成功的游离组织移植和再植的问题。研究表明，在缺血再灌注过程中，白细胞和血管内皮细胞释放多种炎症介质。血管细胞粘附分子-1（VCAM-1）是白细胞上一些粘附受体在内皮上的配体。本研究旨在探讨抗VCAM-1/VLA-4单克隆抗体（MAb）、他克莫司（Tacrolimus）、LECAM-1单克隆抗体（LECAM-1）阻断大鼠皮瓣白细胞-内皮细胞粘附，预防缺血再灌注损伤的作用。游离出由腹壁浅动静脉供应的包括股血管的皮瓣（45× 30 mm）。将股血管与上腹部血管交叉夹闭缺血9小时。治疗组于再灌注前15 min静脉注射抗VCAM-1/VLA-4单抗、他克莫司、LECAM-1单抗，对照组注射生理盐水。通过追踪存活和非存活区域的轮廓来评估皮瓣的存活能力。在接下来的7天内收集数据。结果：追踪分析显示，治疗组皮瓣平均存活面积约为70%，对照组约为20%（P<0.05）。组织学上，治疗组中可以观察到很少的炎症变化，而对照组中观察到明显的损伤。结论：从这项研究中，我们得出结论，治疗皮瓣与单抗VCAM-1，他克莫司，LECAM-1是有效的I-R损伤后9小时的热缺血。